HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases
Adding the brain-penetrant HER2 pill tucatinib to trastuzumab and capecitabine lengthened survival in heavily pretreated HER2-positive metastatic breast cancer, and uniquely the trial included patients with active brain metastases, who also benefited.
Overview
Phase 3 placebo-controlled trial of 612 patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab and T-DM1, randomised 2:1 to tucatinib or placebo with trastuzumab and capecitabine; nearly half had brain metastases, including untreated or progressing lesions.
Overall survival at two years was 44.9 percent with tucatinib against 26.6 percent with placebo (hazard ratio 0.66); progression-free survival among patients with brain metastases at one year was 24.9 versus 0 percent.
- Two-year overall survival 44.9 percent vs 26.6 percent; hazard ratio for death 0.66.
- One-year progression-free survival in patients with brain metastases 24.9 percent vs 0 percent.
Tucatinib-based therapy is the standard for HER2-positive disease with active brain metastases and a standard later-line option overall; it was the first trial to enrol progressing brain metastases and show a systemic drug helps them.
- Diarrhoea and liver enzyme rises were more frequent with tucatinib.
- Trial predates trastuzumab deruxtecan as second-line standard.
Similar pages
not linked directly; found by shared links- Key paperHER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Capecitabine.
- PairingTucatinib + trastuzumab + capecitabine for brain metastases
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
- TrialHER2CLIMB-05
Shares HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Tucatinib, Capecitabine, Trastuzumab.
- IdeaSystemic-first management of HER2-positive brain metastases
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib.
- TrialHER2CLIMB-02
Shares HER2-positive breast cancer with brain metastases, Tucatinib.
- PersonNancy U. Lin
- TrialTucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Shares Tucatinib, Capecitabine, Trastuzumab.